Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Inclusion Criteria: * locoregionally Recurrent or metastatic breast cancer confirmed by histology. * HER-2 Negative Breast Cancer. * At least one measurable lesion according to RECIST 1.1.. * Chemotherapy for recurrent and metastatic lesions should be discontinued for more than 2 weeks. * 18-70 years old. * ECOG PS 0～1. * Participants must have normal organ and marrow function as defined below: ANC ≥ 1.5×109/L,PLT ≥ 75×109/L,Hb ≥ 100 g/L;TBIL≤1.0ULN；ALT and AST≤3×ULN（ALT and AST≤5×ULN if liver metastasis）;BUN and Cr≤1.5×ULN and CCr≥50 mL/min. * life expectancy is not less than 12 weeks. * Signed informed consent. Exclusion Criteria: * Uncontrolled central nervous system metastasis. * Not recovered to 0-1 degree (CTC AE 4.0) from toxic reactions of previous treatments.. * History of allergy to biological agents in the past. * Important organ dysfunction and severe heart disease, including congestive heart failure, uncontrollable arrhythmia, angina, valvular disease, myocardial infarction, and refractory hypertension. * Pregnant or lactating women.. * The patient had a history of other malignant tumors, except for the cured skin basal cell carcinoma and cervical cancer. * The risk of uncontrolled infection, thrombosis and bleeding exists. * A history of immunodeficiency, including HIV positive, HCV, active hepatitis B, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known. * Researchers consider it inappropriate to carry out the study.